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Helicobacter suis infection alters glycosylation and decreases
the pathogen growth inhibiting effect and binding avidity of
gastric mucins
Médea Padra1, Barbara Adamczyk1,2, Bram Flahou3, Mattias Erhardsson1, Gurdeep Chahal1, Annemieke Smet3,4, Chunsheng Jin1,
Anders Thorell5, Richard Ducatelle3, Freddy Haesebrouck3, Niclas G. Karlsson1 and Sara K. Lindén1
Helicobacter suis is the most prevalent non-Helicobacter pylori Helicobacter species in the human stomach and is associated with
chronic gastritis, peptic ulcer disease, and gastric mucosa-associated lymphoid tissue (MALT) lymphoma. H. suis colonizes the
gastric mucosa of 60–95% of pigs at slaughter age, and is associated with chronic gastritis, decreased weight gain, and ulcers. Here,
we show that experimental H. suis infection changes the mucin composition and glycosylation, decreasing the amount of H. suis-
binding glycan structures in the pig gastric mucus niche. Similarly, the H. suis-binding ability of mucins from H. pylori-infected
humans is lower than that of noninfected individuals. Furthermore, the H. suis growth-inhibiting effect of mucins from both
noninfected humans and pigs is replaced by a growth-enhancing effect by mucins from infected individuals/pigs. Thus, Helicobacter
spp. infections impair the mucus barrier by decreasing the H. suis-binding ability of the mucins and by decreasing the antiproliﬁc
activity that mucins can have on H. suis. Inhibition of these mucus-based defenses creates a more stable and inhabitable niche for
H. suis. This is likely of importance for long-term colonization and outcome of infection, and reversing these impairments may have
therapeutic beneﬁts.
Mucosal Immunology (2019) 12:784–794; https://doi.org/10.1038/s41385-019-0154-4
INTRODUCTION
Helicobacter suis is a worldwide spread Gram negative, motile,
spiral-shaped bacterium, which colonizes the gastric mucosa of
60–95% of pigs at slaughter age.1–3 H. suis infection is associated
with chronic gastritis, decreased daily weight gain,4 and the
development of ulcers in the pars oesophagea of the pig
stomach.1,3,5 In the human stomach, H. suis is the most prevalent
non-Helicobacter pylori Helicobacter (NHPH) species.6 H. suis
infection in the human stomach has been associated with the
development of chronic gastritis,7 peptic ulcer disease,8 and
gastric mucosa-associated lymphoid tissue (MALT) lymphoma.9
Although the prevalence of NHPH infection in humans is
low (between 0.2% and 6%,10,11) the risk of developing gastric
MALT lymphoma is higher during NHPH infection compared with
H. pylori infection.12,13
The mucus layer is the ﬁrst barrier gastric pathogens must
overcome for colonization. The main components of the mucus
layer are the densely glycosylated mucin glycoproteins.14,15 In the
healthy human stomach, MUC5AC and MUC6 are the main
secreted mucins, but during disease, MUC2 and MUC5B can also
appear.16,17 Proteomic analysis of mucins from healthy pigs
identiﬁed predominantly MUC5AC, but MUC6 and MUC5B
might also be members of the pig gastric mucin repertoire.18
The high diversity of mucin O-glycans provides an extensive
repertoire of bacterial attachment sites and O-glycans take part in
host–pathogen interactions in the gastrointestinal tract.19–22
Mucus can be beneﬁcial for bacteria by providing nutrients for
growth23,24 and protecting bacteria from the harmful environ-
ment.25 Mucins can also prevent close contact of the pathogen
with the gastric epithelial cells by binding, which may contribute
to removing the bacteria from their niche with the gastric
emptying.26–28 Binding to mucin glycans can also inhibit bacterial
growth and affect expression of virulence genes.29,30
The mucin glycan structures show high variation between
species, individuals, and tissue locations within each indivi-
dual,19,27,31–33 and their production can be affected by bacterial
colonization.31,33 For example, infection with H. pylori has been
demonstrated to alter the expression, turnover rate, and
glycosylation of host gastric mucins.26,34,35 Among mucins isolated
from the stomach of healthy pigs, mass spectrometric analysis
identiﬁed 109 O-glycan structures with high inter-individual
diversity.18 H. suis binding to pig gastric mucins and glycolipids
has been demonstrated, and two mucin-binding modes of this
bacterium have been revealed: binding to structures terminating
with galactose at both neutral and acidic pH and to negatively
charged structures at acidic pH.18
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The aim of the present study was to investigate the effect of
infection-related changes on H. suis interactions with mucins. We
studied the effect of experimental H. suis infection on pig gastric
mucin glycosylation as well as downstream effects of these
infection-induced changes on H. suis binding and growth. Finally,
we examined H. suis binding and growth in response to mucins
isolated from human stomachs with and without H. pylori
infection.
RESULTS
Histological analysis of pig gastric tissue sections after
experimental inoculation with H. suis
Fluorescent in situ hybridization (FISH) revealed H. suis in the mucus
layer overlying the epithelial surface (Fig. 1e) and throughout the
entire length of the pig gastric pits (Fig. 1f), 4 weeks post
inoculation. Signs of inﬂammation were detected in tissue sections
from three out of four infected pigs. The severity of inﬂammation
varied between pigs: no histological signs of inﬂammation were
detected in one pig, whereas in the others the signs ranged from
mild inﬂammation with inﬂammatory cell inﬁltration to severe
inﬂammation with markedly enlarged lymphoid follicles (Figs. 1g,
2a). No signs of inﬂammation were detected in the sham-inoculated
noninfected pig gastric tissue sections (Fig. 1c). The mucus-
producing cells lining the surface and gastric pits produced both
neutral and acidic mucins in both the infected and noninfected
group. We observed a shift in color of mucins from magenta to
purple among H. suis-infected Alcian blue/periodic acid-Schiff
stained tissue sections, which reﬂects an increased level of acidity
of mucin glycans after infection (Fig. 1d, h).
H. suis infection causes decreased MUC5AC levels
Mucins were isolated from the antrum of H. suis-infected (n= 4)
and noninfected (n= 3) pigs, and the mucin-containing fractions
were pooled to provide four samples (surface soluble (SS),
surface insoluble (SI), gland soluble (GI), and gland insoluble (GI))
from each individual for further experiments. The puriﬁed
mucins were analyzed for density, glycan, and MUC5AC content.
Quantiﬁcation of mucins based on their carbohydrate content
revealed that pig gastric mucins were predominantly insoluble in
guanidinium chloride (GuHCl), both in the noninfected (60%)
and H. suis-infected (63%) groups (Fig. 2b). No difference in
Fig. 1 Representative images of pig gastric tissue sections with or without H. suis infection. a, b, e and f Presence and spatial distribution of H.
suis determined by ﬂuorescent in situ hybridization (FISH). a, b Absence of H. suis in sections from noninfected pigs. e, f Presence of H. suis
(bright green) in the surface mucus layer and gastric pits of tissue sections from H. suis-infected pigs. c Hematoxylin and eosin (H&E)-stained
tissue section from a noninfected pig. g H&E-stained section from an H. suis-infected pig showing presence of a lymphoid follicle. d AB/PAS-
stained section of a noninfected pig. h AB/PAS-stained section of an H. suis-infected pig. The AB/PAS stains neutral glycans pink, acidic mucin
glycans blue, and where overlap occurs, the color is magenta
Fig. 2 Gastritis scores and characteristics of puriﬁed pig gastric mucins. a Gastritis scores from experimentally infected and sham-infected
pigs. b Proportion of pig gastric mucins that were soluble versus insoluble in guanidinium chloride (GuHCl). The insoluble mucins were
solubilized by reduction and alkylation. c The density (g/mL) of pig gastric mucins was similar among noninfected and infected pigs (p > 0.05).
d The MUC5AC level was lower among gastric-soluble mucins from H. suis-infected pigs than from noninfected ones. The MUC5AC signal was
normalized for the glycan content of each sample, and the median of the four mucin sources for each pig is presented in the graph (p= 0.05).
Statistics: Mann–Whitney U test. The pig marked in gray carried a second H. suis strain in addition to the strain used in the experimental
infection
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mucin density was observed between noninfected and infected
pigs (p > 0.05, Fig. 2c). Mass spectrometry analysis identiﬁed
porcine MUC5AC in all samples originating from the surface and
in some samples originating from the glands (Table 1). The
analysis indicated lower levels of MUC5AC among mucins from
infected pigs than from noninfected pigs and a decrease in
MUC5AC content in the mucin samples derived from H. suis-
infected pig stomachs compared with the samples from the
noninfected group was conﬁrmed using ELISA (Fig. 2d, p= 0.05).
MUC5B and MUC6 were also identiﬁed in some samples
(Table 1).
H. suis infection changes pig gastric mucin glycosylation
Mucin O-glycans from H. suis-infected (n= 4) and noninfected
(n= 3) pigs were characterized by mass spectrometry. Of the 118
different oligosaccharides that were found (Fig. 3a, Supplemen-
tary Table 1), 93 were present in both groups, 18 were uniquely
detected among the noninfected group, and 7 were only
detected in the infected group (Fig. 3b). Unique structures in
controls contained 0–1 fucose residues and only low amounts of
sialylation (2 structures were monosialylated), while unique
structures in infected group contained up to 2 fucose and/or
sialic acids (Supplementary Table 2). The median (IQR) number of
different glycan structures detected in the gastric mucin samples
was 65 (47–75) in the noninfected group and 45 (36–65) in
the infected group, implying a decrease in the number of
glycan structures on pig gastric mucins upon infection (p ≤ 0.05,
Fig. 3c). H. suis has been shown to bind to acidic (sialylated and/
or sulphated) glycan structures and glycans terminating
with galactose (including structures terminating with type 1
N-acetyllactosamine, Galβ1,3GlcNAc).18 Here, we found an
increase in the relative abundance of acidic (mostly sulfated)
glycan structures (p < 0.05, Fig. 3d) and a decrease in glycan
structures terminating with galactose, including the Galβ1,3Glc-
NAc epitope, in the infected pig gastric mucin samples
compared with the noninfected samples (p < 0.01, Fig. 3d). In
addition, fucosylation (identiﬁed as blood group A and H
epitopes) was also increased in the infected mucin group (p <
0.05, Fig. 3d).
Decreased H. suis-binding ability of mucins isolated from infected
pigs and humans
H. suis bound to all four types of mucins (surface soluble, surface
insoluble, gland soluble, and gland insoluble) isolated from both
noninfected and infected pigs. The level of H. suis binding to
mucins differed between pigs and the four different mucin
sources within each pig, as could be expected based on
differences in glycosylation. In line with previous results,18 the
binding avidity of H. suis to pig gastric mucins was sevenfold
higher at pH 2 than at neutral pH (Fig. 4). At pH 7, H. suis binding
was lower to the mucin samples isolated from infected pigs (p <
0.05), whereas at pH 2 there was only a trend in the same direction
(p > 0.05), matching the changes in H. suis-binding structures
(Fig. 3d). Paralleling these results, the level of binding correlated
with the H. suis density in tissue sections at pH 7 (p= 0.02, r=
−0.92), but not at pH 2 (p= 0.51, r=−0.3). When comparing
mucin binding on a pig level, calculating the mean binding of the
four mucin sources for each pig, the decreased binding ability of
the infected pigs was not statistically signiﬁcant, although the
trend remained (Fig. 4d). The lack of statistical signiﬁcance is likely
due to the low number of noninfected pig samples available.
Since we had analyzed over 70 pigs to obtain three H. suis-free
pigs, we decided to investigate the effect of infection among
human samples instead of attempting to expand the number of
pigs further.
To study the effect of Helicobacter spp. infection on binding of
H. suis to human gastric mucins, binding assays were carried out
using puriﬁed human gastric mucins isolated from the antral part
of the stomach of Helicobacter spp. infected (n= 6) and
noninfected (n= 7) individuals. All samples that were Helicobacter
spp. positive by PCR using Helicobacter genus-speciﬁc PCR
primers were also positive using three H. pylori-speciﬁc primer
pairs, suggesting that 100% of the Helicobacter spp. positive
samples in the patient group were infected with H. pylori. Unlike
pig mucins, human gastric mucins had similar H. suis-binding
avidity at pH 2 and at pH 7 (Fig. 5). Gastric mucins from H. pylori-
infected individuals had decreased H. suis-binding ability com-
pared with those from noninfected individuals, at both neutral
and acidic pH (p < 0.01, Fig. 5). The difference in amplitude
between noninfected and infected mucins was similar for pig and
human samples, but the larger number of human samples
rendered the difference statistically signiﬁcant on an individual
level too (Fig. 5b, d).
Mucins from infected pigs and humans increase H. suis growth
To study the growth of H. suis in response to mucins, we cultured
H. suis in the presence of gastric mucins isolated from infected and
noninfected individuals. H. suis growth decreased by 4% when
cultured in the presence of gastric mucins from noninfected pigs
and increased by 12% in the presence of mucins from infected
pigs, compared with H. suis cultured without mucins (Fig. 6a, b,
p ≤ 0.05). Similar results were obtained after culture with the
human mucins: a 4% decrease in growth was observed with
mucins from noninfected stomachs and a 4% increase in the
presence of mucins from H. pylori-infected individuals (Fig. 6c, p <
0.05).
H. suis growth increases in response to fucose and decreases from
galactose
Mucins can promote or inhibit bacterial growth depending on the
glycan structures they carry.29 The amount of α1,4GlcNAc, a
Table 1. Apomucins in pig gastric mucin samples detected by
proteomic analysis
Sample Apomucin Infection status
MUC5AC MUC5B MUC6 MUC2
Pig1 SS +++ + Noninfected
Pig1 SI +++ +
Pig1 GS
Pig1 GI ++ + +
Pig2 GS
Pig2 SI +++ ++ +
Pig2 GI + +
Pig4 SS + + Infected
Pig4 SI + +
Pig4 GS +++
Pig5 SI + +
Pig5 GS + + +
Pig5 GI ++ +
Pig7 SS +
Pig7 SI ++ +
Pig7 GS +
Pig7 GI ++ + +
Proteomic tandem mass spectrometry analysis was carried out on surface
soluble (SS), surface insoluble (SI), gland soluble (GI), and gland insoluble
(GI) gastric mucins from H. suis-infected and noninfected pigs. The mucin
content was graded from + to +++, based on the sum of all Mascot scores
with which a particular mucin was found in the experiment (+ protein
score 1–800, ++ protein score 800–1600, +++ protein score 1600–2400)
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structure previously suggested to act as a natural antibiotic
against H. pylori,36 was similar among noninfected and infected
pigs (11.7 ± 3.1 vs. 6.6 ± 1.15%, p > 0.05), which suggests that this
structure is not responsible for the difference in H. suis growth
response. We analyzed the relation between the effect of the pig
gastric mucins on H. suis growth, and the relative abundance of
glycan structures identiﬁed on these mucins. We observed a
positive correlation between H. suis growth and the relative
abundance of fucosylated (r= 0.5501, p < 0.01, Fig. 7a) as well as
acidic (r= 0.5485, p < 0.01, Fig. 7b) glycan structures, whereas the
relative abundance of mucin glycans terminating with galactose
(that did not carry fucose and/or acidic glycans) negatively
correlated with H. suis growth (r= 0.6844, p < 0.001, Fig. 7c). No
correlation was identiﬁed with any other terminally located
residues.
To verify the effect of fucose, galactose, and acidic structures
(sialylated and/or sulfated) on H. suis growth, the bacteria were
cultured with fucose, galactose, and NeuAc monosaccharides.
GlcNAc, the abundance of which did not correlate with the growth
of H. suis, was also included in the assay. In line with the
correlations, fucose promoted (p < 0.05) and galactose inhibited H.
suis growth (p < 0.01), whereas GlcNAc had no effect (p > 0.05),
compared with H. suis growth in the absence of added
monosaccharides (Fig. 8). NeuAc did not affect H. suis growth (p
> 0.05), which suggests that instead sulfation may stimulate
growth (sulfation was also more abundant), although the
association with acidic glycans might also not be causative.
DISCUSSION
In the present study, we showed that experimental H. suis
infection changed the mucin composition and glycosylation,
which decreased the amount of H. suis binding glycan structures
in the pig gastric mucus niche. Similarly, the H. suis-binding and
Fig. 3 Glycosylation of gastric mucins from H. suis-infected and noninfected pigs. a Relative abundance (%) of each of the identiﬁed glycan
structures among H. suis-infected and noninfected pig gastric mucin samples. The full list of identiﬁed glycans is available in Supplementary
Table 1. b Distribution of common and unique mucin glycan structures in noninfected and infected pig groups. c Number of glycan structures
identiﬁed in individual gastric mucin samples isolated from noninfected and infected pigs. d H. suis infection-associated alterations in the
relative abundance of terminal epitopes on pig gastric mucins. Many of the structures are branched, leading to that the sum of the terminal
structures is above 100%. The relative abundance of fucosylated and acidic glycan structures increases, whereas that of the galactose-
terminating glycan structures (including Galβ1,3GlcNAc) decreases with infection. Statistics: *p < 0.05, **p < 0.01, two-way ANOVA, data are
plotted as mean ± SEM
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growth-inhibiting ability of gastric mucins from H. pylori-infected
human stomachs was lower than those from noninfected
individuals.
After experimental infection, we detected H. suis in the mucus
layer covering the gastric epithelial surface as well as in the entire
length of gastric pits. Experimental H. suis infection decreased the
amount of MUC5AC in the tissue, in line with previous
observations in H. pylori-infected human gastric tissues.37 Among
puriﬁed pig gastric mucins, we identiﬁed 118 different oligosac-
charides, the number and composition of which structures
differed between infected and noninfected pigs. Fewer glycan
structures were identiﬁed among infected pigs compared with
uninfected pigs, in spite of fewer pigs in the latter group. This is in
contrast to observations on pig colonic mucins, where Brachyspira
hyodysenteriae infection led to production of an increased array of
glycan structures.33 The disparate glycan responses could be due
to differences between the infecting pathogens, host immunolo-
gical responses, or body locations.
In addition to the experimental pig infection, we also analyzed
H. suis interactions with human gastric mucins isolated from
H. pylori-infected and noninfected individuals. Due to the low
prevalence of H. suis, and limited number of people that go
through gastrectomy, it was not feasible to collect a sufﬁcient
number of stomachs from H. suis-infected humans to do
the analysis on speciﬁcally H. suis-infected human specimens.
However, the similar effects on both H. suis binding and
growth of mucins from pigs experimentally infected with H.
suis and humans naturally infected by H. pylori compared with
mucins from their noninfected counterparts suggests that
infection by these pathogens lead to similar changes regardless
of species.
We have previously demonstrated that H. suis binding occurs
via two modes of adhesion: (1) to galactose-terminating structures
at both neutral and acidic pH and (2) to negatively charged
structures at acidic pH.18 In contrast to the large variation in
mucin-binding speciﬁcity and avidity present among H. pylori
strains,38 binding of four H. suis strains isolated from primates and
pigs to pig and human mucins was very similar,18 suggesting low
inter-individual variation in binding speciﬁcity among H. suis
strains. Here, we showed that the binding level of H. suis to pig
gastric mucins was around sevenfold higher at pH 2 than at pH 7,
regardless of the infection status of the pigs. At pH 7, we observed
decreased binding of mucins isolated from the infected pigs to H.
suis, which can be explained by the decreased level of galactose-
terminating mucin glycans in infected pig mucins providing less
potential binding sites for the bacteria. There was no binding
difference between the infected and noninfected pig mucins at
pH 2, which likely is due to the fact that at acidic pH, adhesion of
H. suis also occur via a charge-dependent binding mode to acidic
glycans. Since the amount of acidic structures increased after
infection, that compensates for the loss of adhesion targets
caused by the decreased terminal galactose. Human mucins from
infected individuals were less efﬁcient at binding to H. suis than
mucins from noninfected individuals at both pH 2 and pH 7, and
the avidity was similar at both pHs. Gastric mucin glycosylation
changes affecting pathogen binding have been shown also after
infection with H. pylori.26 H. pylori binds to Leb and SLex blood
group antigens on gastric mucins via blood group antigen-
binding adhesin (BabA) and sialic acid-binding adhesin (SabA),
respectively, and infection with this pathogen decreases the level
of Leb and increases the level of sialylation in the gastric
mucosa.26,39 These glycosylation changes increase H. pylori
Fig. 4 H. suis binding to pig gastric mucins isolated from pigs with or without H. suis infection. a, b H. suis binding to pig gastric mucin samples
at pH 2. a The data points represent the binding to surface soluble, surface insoluble, gland soluble, and gland insoluble mucins from each
pig. b The data points represent the average binding signal from the four mucin sources from each pig. c, d H. suis binding to pig gastric
mucin samples at pH 7. c The data points represent the binding to surface soluble, surface insoluble, gland soluble, and gland insoluble
mucins from each pig. d The data points represent the average binding signal from the four mucin sources from each pig. ○ Surface soluble,
● Gland soluble, □ Surface insoluble, ■ Gland insoluble,▲Mean binding value of the four mucin sources per pig. The pig marked in gray
carried a second H. suis strain in addition to the strain used in the experimental infection. Statistics: a, c: *p < 0.05, two-way ANOVA, the bars
represent mean ± SEM, b, d, the bars represent median with range. The results were reproduced twice
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binding via SabA and via the charge-dependent binding modes,
but decrease binding via BabA to fucosylated structures, including
Leb.26,40 Although the interacting molecules differ between H. suis
and H. pylori, the overall effect of decreased mucin binding ability
at neutral pH after infection is a common feature, as binding
avidity via BabA generally is higher than via SabA.30
Mucins derived from different individuals and disease states
have been shown to have growth promoting or inhibitory
effect.29,30 For instance, the growth of H. pylori can be inhibited
by mucins containing α1,4GlcNAc-capped O-glycans,36 and H.
pylori adhesion to mucins can also have growth inhibitory effect
by aggregate formation.30 Here, we observed that both porcine
and human gastric mucins isolated from infected individuals had a
growth-promoting effect, whereas mucins from noninfected
individuals inhibited the growth of H. suis independently of
α1,4GlcNAc-capped O-glycan abundance. Instead, we observed a
positive correlation between growth and the abundance of acidic
and fucosylated structures and a negative correlation with the
abundance of galactose terminating structures on the mucins, and
culture with fucose and galactose monosaccharides supported
these effects. We have previously cultured another bacteria
(Aeromonas salmonicida) with twice as high concentration of
galactose without inhibition of growth,21 suggesting that the
inhibition of growth seen in the current study is not affecting all
bacteria. Each mucin carried 35–75 glycans, and the growth
response to the mucins is thus likely to be the sum of multiple
glycans.
H. pylori-infected children and rhesus monkeys secreting
mucins with less H. pylori-binding capacity, develop higher H.
pylori density and more severe gastritis,26,27 supporting the idea
that the ability of secreted mucins to bind to H. pylori protects the
gastric epithelium. Furthermore, mice lacking the Muc1 mucin are
more susceptible to infection by H. pylori,41 and MUC1 acts as a
releasable decoy for H. pylori binding to the gastric epithelial
surface.28 Thus, decreased ability of mucins from infected pigs and
humans to bind H. suis implies that Helicobacter spp. infection
inhibits binding and subsequent removal of the pathogen from
the gastric niche. Furthermore, increased H. suis growth in
response to mucins from infected pigs and humans would allow
faster growth. In addition, we have previously shown that gastric
mucin production is impaired during H. pylori infection.35
Helicobacter spp. infections thus inhibit three aspects of the
mucin-based defense, which in turn creates a more stable and
growth-enhancing environment for H. suis to colonize long-term.
In addition to creating a more hospitable niche for itself,
Helicobacter infection might also lead to increased susceptibility
to infection by additional strains or Helicobacter species. Indeed,
infection with more than one H. pylori strain has been previously
reported,42,43 and coinfection with H. pylori and NHPH strains has
also been described.44,45
Although the average differences in growth regulation and
binding between mucins from infected versus noninfected
individuals were relatively small, the long-term effect in these
life-long infections is likely to have a major impact on pathogen
density. Furthermore, the difference between the highest and
lowest effect of mucins is substantial: for growth, the difference
was 35% after 13 h and for binding it was 20-fold. These effects
might contribute to the fact that some individuals are asympto-
matic carriers whereas others develop severe disease from
Helicobacter spp. colonization.
Fig. 5 Binding of H. suis to human gastric mucins isolated from individuals with or without H. pylori infection. a, b H. suis binding to human
gastric mucin samples at pH 2. a The data points represent the binding to surface-soluble, surface-insoluble, gland-soluble, and gland-
insoluble mucins from each individual. b The data points represent the average binding signal from the four mucin sources from each
individual. c, d H. suis binding to human gastric mucin samples at pH 7. c The data points represent the binding to surface soluble, surface
insoluble, gland soluble, and gland insoluble mucins from each individual. d The data points represent the average binding signal from the
four mucin sources from each individual. Statistics: a, c: **p < 0.01, two-way ANOVA, the bars represent mean ± SEM, b, d: *p < 0.05,
Mann–Whitney U test, the bars represent median with range. ○ Surface soluble, ● Gland soluble,□ Surface insoluble,■ Gland insoluble,▲
Mean binding value of the four mucin sources per pig. The pig marked in gray carried a second H. suis strain in addition to the strain used in
the experimental infection. The graphs are representative of two experiments
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In conclusion, we showed that experimental H. suis infection
changed the mucin composition and glycosylation. These changes
decreased the amount of H. suis-binding glycan structures in the
pig gastric mucus niche and decreased the H. suis growth
regulating effects of the mucins. Similarly, the H. suis-binding and
growth-inhibiting ability of mucins from H. pylori-infected human
stomachs was lower than those from noninfected individuals.
Together with the observation that gastric mucin production is
impaired during H. pylori infection,35 this demonstrates that
Helicobacter spp. infections inhibit three aspects of the mucin-
based defense. Inhibition of these mucus-based defenses creates
a more stable and inhabitable niche, likely of importance for long-
term colonization and outcome of infection. Helicobacter spp. is a
group of pathogens that chronically colonize the gastric mucosa
of half the world’s population, cause morbidity and mortality,
require severe antibiotic treatment to eradicate, and are prone to
developing antibiotic resistance. Eradicating Helicobacter spp. is
beneﬁcial from a cancer prevention perspective,46 but considering
the increasing problems with antibiotic-resistant bacteria, it is not
justiﬁed to treat all infected people with antibiotics. Therapeutics
reversing the impairments of the mucin-based defenses may
provide an alternative avenue to explore in order to treat
infections.
METHODS
H. suis culture conditions
H. suis strain HS1 was cultured in biphasic Brucella culture plates
(BD BBL) containing 20% fetal bovine serum (FBS) (HyClone), Vitox
supplement (Oxoid), Skirrow Campylobacter selective supplement
Fig. 6 H. suis growth in the presence of gastric mucins from infected or noninfected pigs and humans. a, b Growth of H. suis in the presence of
pig gastric mucins isolated from H. suis infected or noninfected pigs. The results are presented in relation to growth in the absence of mucins.
a H. suis growth in response to four mucin sources per individual (i.e., surface soluble, surface insoluble, gland soluble, and gland insoluble
mucins). Statistics: ***p < 0.001, two-way ANOVA, the bars represent mean ± SEM. bMean H. suis growth in response to the four mucin sources.
The graph shows one data point per individual. Statistics: *p ≤ 0.05, Mann–Whitney U test, the bars represent median with range. c H. suis
growth in the presence of human gastric mucins isolated from H. pylori-infected or noninfected individuals. The results are presented in
relation to H. suis cultured without mucins. Statistics: *p < 0.05, Mann–Whitney U test, the bars represent median with range. The graph shows
one data point per individual.○ Surface soluble,● Gland soluble,□ Surface insoluble,■ Gland insoluble,▲Mean growth in response to the
four mucin sources per pig. The pig marked in gray carried a second H. suis strain in addition to the strain used in the experimental infection.
The graphs are representative of two experiments
Fig. 7 Relation between the effect of pig gastric mucins on H. suis growth and the relative abundance of glycan epitopes carried by these
mucins. a, d Relation between H. suis growth and the relative abundance of fucosylated structures. b, e Relation between H. suis growth and
acidic glycans. c, f Relation between H. suis growth and mucin glycans with terminal galactose. a-c The data points represent values of four
mucin source per individual. d–f The data points represent the average values of four mucin source per individual. Statistics: Pearson’s
correlation test
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(Oxoid), and 5mg/L amphotericin B. The pH of the agar was
adjusted to 5 with 37% HCl. One mL sterile Brucella broth with pH
5 was added onto the agar surface. The bacteria were cultured
under microaerobic conditions (10% CO2, 5% O2) at 37 °C for
24–42 h.
Samples
Porcine. A total of 32 medicated, early weaned piglets (Rattlerow
Seghers sow x Piétrain boar) were used (EC approval number
EC2012/129). The protocol used has previously been shown
effective in limiting H. suis infection.4 Immediately after birth (day
0) as well as on day 1 and 2, the piglets received 75mg of
amoxicillin intramuscularly (IM) (Duphamox LA™, Pﬁzer, USA). On
day 3, the piglets received 2.5 mg/kg of tulathromycin IM (Draxxin,
Pﬁzer). From day 3 to day 11, all animals received 150 mg of
amoxicillin IM. On day 9, the piglets were weaned and transferred
to barrier maintained facilities at the Faculty of Veterinary
Medicine, Ghent University. They received a milk replacement
diet using a commercial liquid feeder until the age of 35 days. At
4 weeks of age, 16 piglets were orally inoculated with 5 mL of
Brucella broth (Becton Dickinson, Erembodegem, Belgium) with a
pH of 5, containing 5 × 108 viable H. suis (strain HS1) per mL. The
16 other piglets were sham-inoculated with 5 mL of sterile Brucella
broth with a pH of 5. All pigs were euthanized 4 weeks after the
experimental infection/sham administration. The Helicobacter
infection status of the pig stomachs was determined by FISH on
gastric histology samples and PCR on gastric mucus scrapings.2,4
Only two out of 16 sham-inoculated pigs were deemed H. suis free
by both PCR and FISH, indicating that the medicated early
weaning protocol was not entirely successful. To increase the
sample number in the negative control group, we located another
4-month-old H. suis-free pig from a different cohort. We tried to
further increase the number of noninfected controls by collecting
stomachs from slaughterhouses, but PCR performed on stomachs
from 60 pigs determined only one free of H. suis, and even this pig
showed signs of severe inﬂammation and had to be excluded
from further experiments. In the H. suis inoculated group, all the
pigs were determined H. suis positive with both FISH and PCR.
However, multilocus sequence typing47 revealed the presence of a
different strain of H. suis in addition to the strain used for
experimental infection in 5 out of 16 pigs. Among the four pig
samples included in the current study, three carried only the
inoculated strain, whereas the fourth pig at a late stage was
discovered to carry both the inoculated strain and another strain.
Since the glycan proﬁle and histology from this sample was similar
to the other three samples, we did not exclude data from this pig.
Human. Human gastric macroscopically normal samples were
obtained from obese patients in conjunction with vertical sleeve
gastrectomy after giving written informed consent (Ersta Hospital,
Sweden). The study protocol was approved by the regional ethics
board (Regionala etikprövningsnämnden i Göteborg, Dnr 753-14).
We randomly selected six Helicobacter spp. positive (gastritis
scores 1–4, age 38–51, 5 females, 1 male) and seven Helicobacter
spp. negative samples as controls (gastritis scores 0–1, age 28–60,
5 females, 2 males).
Histology methods
AB/PAS, H&E, and FISH staining were performed as previously
described.32,35 The level of inﬂammation was scored blinded on
H&E-stained sections. On pig tissue sections, inﬂammation scores
were graded from 0 to 3 (0: no inﬂammatory cells or follicle, 1:
moderate level of cell inﬁltration, no follicle, 2: widespread cell
inﬁltration and one or two follicles and 3: widespread cell
inﬁltration and multiple large follicles). On human tissue sections,
inﬂammation scores graded from 0 to 5 (0: no inﬂammatory cells
or follicle, 1: moderate level of cell inﬁltration, no follicle, 2:
moderate level of cell inﬁltration one or two small follicles, 3:
widespread cell inﬁltration and one or two small follicles 4:
widespread cell inﬁltration and multiple follicles 5: widespread cell
inﬁltration and multiple large follicles).
PCR for detection of Helicobacter spp. in human gastric samples
Cultured H. pylori and a strongly positive patient sample were
used as positive controls. The DNA from the samples and controls
was puriﬁed with the QIAamp DNA Mini (Qiagen) kit according to
the manufacturer’s instructions. Helicobacter genus (16S) and
H. pylori speciﬁc (ureC, glmM, and hspA) primers (Table 2)
weresynthesized by Euroﬁns Genomics. The PCR was performed
in 20 µL of reaction volumes consisting of a ﬁnal concentration of
1x Invitrogen™ Platinum™ Hot Start PCR Master Mix (2 × , Thermo
Table 2. Primers used for PCR
Gene Primer sequence (5′->3′) Product size bp Source
Hcom 1 Forward– GTA AAG GCT CAC CAA GGC TAT 389 49
Hcom 2 Reverse – CCA CCT ACC TCT CCC ACA CTC
ureC Forward– AAG CTT TTA GGG GTG TTA GGG GTT T 294
Reverse – CTG CTT GCT TTC TAA CAC TAA CGC
glmM Forward– TCT AAA AAC GCC CTT TCT TCT CA 130 50
Reverse – ATT CGC TCA CAA ACT TAT CCC C
hspA Forward– ACA GCA AGA TTC ATG CTC TT 134 51
Reverse – CAG AAA TCG TTT TAG ACG GCA
Although the ureC and the glmM primers likely are the same protein, we used this terminology to be consistent with previous literature
Fig. 8 Effect of monosaccharides on the H. suis growth. H. suis
growth in the presence of monosaccharides (50 µg/ml). The values
are presented as percentage growth difference from parallel
cultures without added monosaccharides. Statistics: *p < 0.05, **p
< 0.01, ns p > 0.05, one-way ANOVA, Dunnett’s multiple comparisons
test. The data are plotted as mean ± SEM
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Fisher Scientiﬁc), 0.5 pmol/µL forward and reverse primer, and 5
ng/µL template. Samples were run in triplicates together with
positive and negative controls. The ampliﬁcation program
consisted of 94 °C for 5 min, 35 cycles (94 °C for 30 s, annealing
at 60 °C (glmM, ureC, Hcom), 55 °C (hspA) for 30 s, extension at
72 °C for 30 s) followed by a ﬁnal extension at 72 °C for 7 min.
Ampliﬁcation was carried out using an Applied Biosystems 2720
Thermal Cycler (Thermo Fisher Scientiﬁc). The PCR products were
separated using a 2% agarose gel, stained with ethidium bromide,
and visualized under UV light.
Isolation and characterization of gastric mucins
Mucins were isolated from pig and human gastric tissue from the
antrum and analyzed for glycan content and MUC5AC as
previously described.18 Brieﬂy, the surface and glandular mucus
were separated by gentle and harsh scraping of the tissue with a
glass microscope slide. Mucins were extracted from the scrapings
in ﬁve volumes of extraction buffer (6 M GuHCl, 5 mM EDTA,
10mM sodium phosphate buffer, pH 6.5) containing 0.1 M PMSF
and dispersed with Dounce homogenizer and stirred at 4 °C
overnight. The insoluble material was removed by centrifugation
at 23,000 x g for 50 min at 4 °C (Beckman JA-30 rotor). The pellet
was reextracted twice with 10 mL of extraction buffer and the
pooled supernatants corresponded to the GuHCl-soluble mucins.
The ﬁnal pellet was reduced with 10 mL of 10 mM 1,4-
dithiothreitol (DTT) in reduction buffer (6 M GuHCl, 5 mM EDTA,
0.1 M Tris-HCl buffer, pH 8.0) for 5 h at 37 °C followed by alkylation
with 25mM iodoacetamide overnight in the dark at room
temperature. The suspension was centrifuged as above. The
supernatant corresponded to GuHCl-insoluble mucins and the
pellet was discarded. Both the GuHCl-soluble and GuHCl-insoluble
materials were dialyzed three times against extraction buffer using
a dialysis tube with 14 kDa pore size (Sigma-Aldrich). The mucins
were isolated by isopycnic density-gradient centrifugation in CsCl/
4 M GuHCl, as previously described.18 The density-gradient
fractions were analyzed for DNA content by UV light absorbance
at 280 nm, and the density of the fractions was measured using a
Carlsberg pipette as a pycnometer. The use of chaotropic agent
(GuHCl) disassociates noncovalent bonds and the density-gradient
centrifugation separates less glycosylated proteins/peptides from
the mucin-containing fractions.18 Some of the pig gastric mucin
samples were contaminated with DNA, therefore a second
density-gradient centrifugation was carried out on all pig gastric
samples to further purify mucins from DNA in CsCl/0.5 M GuHCl.18
The mucin-containing fractions were then pooled into four
samples (surface soluble, surface insoluble, gland soluble, and
gland insoluble) from each individual.
Mass spectrometric analysis
Proteomic analysis was performed as previously described.18
Peptide MS/MS spectra were searched against UniProt and NCBI
pig protein databases using Mascot server (v.2.2.04, Matrix
Science Inc., MA, USA) with an in-house built mucin database.
The ﬁnal sequences of S. scrofa Muc5ac and Muc5b used in this
project are not entirely complete and are not guaranteed to be
correct in every amino acid position, but nevertheless provided
the ability to efﬁciently discriminate between MUC5AC and
MUC5B.18 For S. scrofa MUC2 and MUC6, we used protein
sequences available in Genbank, XP_013845199.1 (MUC2) and
XP_013845183.1 (MUC6). Both of these entries seem to comprise
near full-length mucin sequences. Only peptides with a mass
deviation lower than 10 ppm were accepted, and at least two
peptide sequences with manual inspection were used for
positive protein identiﬁcation.
Sample preparation for LC-MS/MS analysis of glycans: approx.
20 μg of puriﬁed porcine gastric mucins were dot-blotted onto the
polyvinylidene ﬂuoride (PVDF) membrane (Immobilin P, Millipore,
Billerica, MA, United States), stained with Alcian Blue 8GX Alcian
Blue 8GX (Sigma-Aldrich) for 1 h at RT and destained with
methanol. The O-glycans were released and analyzed by LC-MS as
described previously.18
Binding assay
Biotinylation of bacteria was performed as previously described.48
We have previously shown that binding is similar with
biotinylated and un-biotinylated H. suis,18 although the assay
with biotinylated bacteria have a lower and more consistent
background signal. Mucin samples were diluted to 4 µg/mL in
0.5 M GuHCl and coated on Nunc™ Microplate Immuno Polysorp
96-well plates (Thermo Fisher Scientiﬁc) overnight at 4 °C. The
plates were washed three times with washing buffer (PBS with
0.05% Tween 20), and the wells were blocked for 1 h with 1%
blocking reagent for ELISA (Roche). After discarding the blocking
buffer, biotinylated bacteria were diluted to an OD600 of 0.05 in
blocking buffer (pH 2 or pH 7). The bacterial suspension was
added to the plates, which then were incubated for 2 h at 37 °C
and on a shaker (120 rpm). The plates were washed three times
and then incubated with blocking buffer containing 1 µg/mL of
horseradish peroxidase-conjugated streptavidin for 1 h at room
temperature. After three further washing steps, TMB substrate
was added and the plates were incubated for 15 min at room
temperature. The reaction was stopped by adding an equivalent
amount of 0.5 M H2SO4 and the plates were read in a microplate
reader at 450 nm.
H. suis growth assay with mucins and monosaccharides
H. suis growth was determined by RealTime-Glo™ MT Cell Viability
Assay (Promega), in which the luminescent signal is proportional
to the number of viable cells. Prior to the assay, the temperature
of MT Cell Viability Substrate and NanoLuc® Enzyme and the
culture medium (Brucella broth (pH 5) containing 20% FBS) was
equilibrated to 37 °C. H. suis was harvested from agar plates,
centrifuged at 2500 × g for 3 min, and resuspended in the culture
medium. Mucin samples were dialyzed using 12 kDa dialysis tubes
(Sigma-Aldrich); four times against 2 M NaCl, then two times
against PBS. The mucin and monosaccharide samples were diluted
in PBS. H. suis with a ﬁnal OD600 of 0.2 was added to 96-well white
opaque-walled tissue culture plates in the presence of 50 μg/mL
mucin or monosaccharide. Adding dialyzed mucin isolation buffer
instead of mucin to the culture medium was used as a control for
normal growth. For the pig mucins, the growth in response to
each mucin source was analyzed, and the mean growth per pig
was calculated based on these results. For the human samples, the
four mucin sources were pooled before the assay. MT Cell Viability
Substrate and NanoLuc® Enzyme were added to the bacterial
suspension according to the manufacturer’s instructions. The
plates were covered with gas permeable seal (Diversiﬁed Biotech)
and incubated at 37 °C inside a plate reader (CLARIOstar, BGM
labtech GmbH, Ortenberg, Germany) for 24 h at 37 °C under
microaerobic conditions (10% CO2, 5% O2). Luminescence reading
was measured at every 30 min.
Statistical analyses
Statistical analyses were performed using the GraphPad Prism
7 software. Mann–Whitney U tests were used to analyze
differences between infected and noninfected groups, where
the data were presented per individual. D’Agostino–Pearson
omnibus normality tests were performed prior to performing
analyses of variance (ANOVA), and the datasets passed the tests.
Two-way ANOVAs were performed to analyze differences between
infected and noninfected groups, where the data were presented
per mucin source. Differences between more than two groups and
a single control group were analyzed by one-way ANOVA followed
by Dunnett’s multiple comparisons test. Relations between
parameters were analyzed by Pearson’s correlation test. Differ-
ences with p ≤ 0.05 were considered signiﬁcant.
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